Available Until 2/4/2025

Intensive Studies for Recertification: Pharmacotherapy (Cert # L249013)

ACPE Numbers: Various – see listing below
Content Release Date: 02/07/2024
Expiration Date: 02/04/2025
Activity Type: Application-based
CE Credits: 6 contact hours
Activity Fee: $105 (ASHP member); $160 (non-member)

Activity Overview

These activities were presented as part of the 2023 Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting should not claim ACPE credit again.

The Intensive Studies Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy. 

The Pharmacotherapy Intensive Studies Recertification Package consists of 4 activities (see table below) and provides up to 6 contact hours of continuing pharmacy education and/or recertification credit. 

These activities are part of the ASHP professional development program for BCPS recertification approved by BPS. For pharmacists who maintain more than one certification, two of the activities are approved for multiple specialties (see table below).

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Antifungal pharmacotherapy
  • Opioid prescribing and non-opioid pain management
  • Drug allergy management
  • Recognition and treatment of hyperactive delirium with severe agitation

Board certified pharmacists are eligible to receive up to 6 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost. 

ASHP is approved by BPS as a provider for the recertification of BCPS.

Learning Activity

Passing Score

Credit Information

Updates in Antifungal Pharmacotherapy: Resistance, Challenges, New Options


1.50 Contact Hours

ACPE: 0204-0000-23-313-H01-P

No Pain, No Gain: Updates in Opioid Prescribing and Non-Opioid Pain Management


1.50 Contact Hours

ACPE: 0204-0000-23-326-H08-P

Making the Grade: Approaches to Drug Allergy Management


1.50 Contact Hours


ACPE: 0204-0000-23-239-H01-P

Dazed and Confused: Clearing the Haze for the Recognition and Treatment of Hyperactive Delirium with Severe Agitation


1.50 Contact Hours

ACPE: 0204-0000-23-265-H01-P

Updates in Antifungal Pharmacotherapy: Resistance, Challenges, New Options
ACPE #: 0204-0000-23-313-H01-P

  • Compare differences in new and pipeline antifungal agents.
  • Evaluate the impact of antifungal resistance on patient care.
  • Design a treatment regimen for a patient with a fungal infection caused by a resistant organism.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

No Pain, No Gain: Updates in Opioid Prescribing and Non-Opioid Pain Management
ACPE #: 0204-0000-23-326-H08-P

  • Develop treatment plans based on patient-specific factors to optimize safe and effective pain management.
  • Counsel patients on realistic pain outcomes, such as reduced pain and improved function.
  • Modify care plans for patients with opioid use disorder, a history of overdose, or patients that experience opioid-related adverse events.
  • Identify non-opiate pharmacologic interventions for patients on medication-assisted treatment.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Making the Grade: Approaches to Drug Allergy Management
ACPE #: 0204-0000-23-239-H01-P

  • Compare and contrast skin testing, graded challenges, and desensitization as approaches to drug allergy management.
  • Evaluate current literature on drug allergy management approaches and their impact on patient outcomes.
  • Design an appropriate care plan given the results of a patient's allergy assessment.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Dazed and Confused: Clearing the Haze for the Recognition and Treatment of Hyperactive Delirium with Severe Agitation
ACPE #: 0204-0000-23-265-H01-P

  • Evaluate strategies that the care team can employ to promptly recognize a patient presenting with hyperactive delirium with severe agitation, as well as potential causes of the delirium.
  • Recommend an effective treatment regimen for the management of a patient presenting with hyperactive delirium with severe agitation.
  • Develop monitoring strategies for the medications used for hyperactive delirium with severe agitation.
  • Design an effective protocol or institutional guidelines to ensure patient and staff safety throughout transitions of care for patients presenting with hyperactive delirium with severe agitation.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) and Board Certified Critical Care Pharmacist (BCCCP) recertification credit.

Faculty bios

Robbie L. Christian, PharmD, AAHIVP, BCIDP
Infectious Diseases Clinical Pharmacy Specialist / ID PGY2 Residency Program Director
VA Northeast Ohio Health Care
Cleveland, Ohio

Yewande Dayo, PharmD, BCIDP
System Antimicrobial Stewardship Clinical Pharmacist
Ochsner Health
New Orleans, Louisiana

Brandon K. Hawkins, PharmD, AAHIVP, BCIDP
Assistant Professor
University of Tennessee Health Science Center College of Pharmacy
Knoxville, T

Jennifer L. Koehl, PharmD, BCPS
Emergency Medicine Clinical Specialist
Massachusetts General Hospital
Boston, Massachusetts

Megan E. Musselman, PharmD, MS, BCCCP, BCPS
Clinical Pharmacy Specialist, Emergency Medicine/PGY2 Emergency Medicine Pharmacy Residency Program Director
North Kansas City Hospital
Kansas City, Missouri

David Shifrin, PharmD, BCPS
Emergency Medicine Clinical Pharmacy Specialist
MedStar Washington Hospital Center
Washington, District of Columbia

Andrew P. Smith, PharmD, MBA, BCPS, BCCCP
Emergency Medicine Clinical Pharmacist Specialist
Scripps Mercy San Diego
San Diego, California

Kayla R. Stover, PharmD, FCCP, FIDSA, BCPS, BCIDP
Associate Professor of Pharmacy Practice
University of Mississippi School of Pharmacy
Department of Pharmacy Practice
Jackson, Mississippi

Sue Dombrowski, MS, RPh
Snehal Bhatt, PharmD, AACC, BCPS-AQ Cardiology, FASHP*
Christopher Betz, PharmD, BCPS, FASHP, FKSHP*
Douglas Slain, PharmD, BCPS, FASHP*
Jennifer L. Thackray, PharmD, BCPPS, BCPS*  

*Content Matter Experts

Hakeem Abayomi, PharmD, BS, BCPS, BCPPS, BCIDP, BCCCP
Uzma Ahmed, PharmD, BCCCP
Edward Alvarez, PharmD, BCIDP, BCCCP
Mary Archambault, PharmD, BCPS
Eyerusalem Befkadu, PharmD, BCPS
Neha Belter, PharmD, BCPS
Matthew Bledsoe, PharmD, MBA, BCPS
Tiffany Boehland, PharmD, BCPS
Eugene Bush, BSPharm, PhD, Pharmacol, BCPS, BCCCP
Katherine Conway, PharmD, BCPS
Adamma Davis, PharmD, BCPS, BCNSP
Chris DeMella, PharmD, BCCCPS
Milouse Dornevil, PharmD, BCPS, BCNSP
Gabrielle Driller, PharmD, BCPS
Andrea Dunlop, PharmD, BCPS
George Dydek , PharmD, BCPS
Lisa Dykes, PharmD, BCEMP, BCPS
Ahmed Eid, PharmD, BCPS
Leah Frantzen, PharmD, BCPS
Geneen Gibson, PharmD, BCPS
Julie Giddens, PharmD, BCPS, BCIDP
Parna Haghparast, PharmD, BCPS
Yorika Hammett, PharmD, BCCCP
Erin Hellickson, PharmD, BCPS
Stacy Henry, PharmD, BCPS
Rebecca Hilton, PharmD, BCCCP
Mylinh Ho, PharmD, BCPS, BCCCP
Allyson Howard, PharmD, BCPS
Miranda Howland, Pharm D, BCCCP
Jolie Jantz, PharmD, BCPS, CDCES
LilyAnn Jeu, PharmD, MHA, BCPS, CPHQ, CPPS
Sheena Jindal, PharmD, MS, BCPS
Jason Jones, BCPS, BCCCP
Bethany Jumps, PharmD, BCPS
Jennifer Katzianer, PharmD, BCPS
Jonathan Kempfert, PharmD, BCPS
Savannah Knepper, BCPS
Kathleen Kusey, PharmD, BCPS
Noelle Kwan, PharmD, BCPS
Nancy Laux, BSPharm, PharmD BCPS BCGP
daisy leong, PharmD, BCPS, BCSCP
Steven Lo, PharmD, BCPS
Melanie Madorsky, PharmD, BCPS, BCCP, BCCCP
Jamie Mahan, PharmD, BCPS
Erin Mangum, PharmD, BCPS
Melissa Marsinko, PharmD, BCPS
Kristen McKnight, PharmD, BCPS, CDCES, CPP
Margo Mekheil, PharmD, BCPS, BCCCP
Matthew Morrison, PharmD, BCPS, BCEMP
Oussayma Moukhachen, PharmD, BCPS, BCCCP
Melissa Murphy, PharmD, BCPS
Ria Lei Marie Natividad, PharmD, BCPS, CPh
Katie Nesbitt, PharmD, BCPS
Janine Ohler, PharmD, BCPS
Zoon Park, PharmD
Brittany Parker, PharmD, BCPS, CPPS
Dipti Patel, PharmD, BCCCP, BCIDP, BCPS
Angela Paul, PharmD, BCPS
Amanda Penland, PharmD, BCPPS
Tracy Peterson, PharmD, BCPS, BCCCP
Travis Preau, PharmD,BCPS
Bambi Randall, PharmD, BCPS
Kevin Reynolds, PharmD, BCPS
Kristen Reynolds, PharmD, BCPS, CSP
Antonio Rivera, PharmD, BCPS, MBA
Kristen Rychalsky, PharmD, BCPS, BCOP
Gabriella Sarver, PharmD, BCPS, BCCCP
Gabriele Sasso, PharmD, BCPS
Kasey Schmidt, PharmD, BCPS
Bridger Singer, PharmD, BCPS, BCCCP
Bovornpat Suriyapakorn, PharmD, BCPS, BCGP
Yen Tang, PharmD, BCPS
Elizabeth Tesch, PharmD, BCPS, BCCP
Lynette Varghese, PharmD, BCPS, BCGP, CDCES
Tyler Vest, PharmD, MS, BCPS, BCSCP, FNCAP
Anh Vu, PharmD, BCPS, BCCCP
Chelsea Wampole, PharmD, BCCCP
Stephanie Weightman, PharmD, BCPS, BCPPS, BCEMP
Corrie Weiland, PharmD, MBA, BCPS
Stephanie Yang, PharmD, BCPS
Rachel Zander, PharmD, BCPS
Barbara Zarowitz, PharmD, BCPS, BCGP
Marisa Zweifel, PharmD, BCPS

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

  • Kayla Stover – Advisor: Cidara Therapeutics

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.